Projects per year
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. Obesity-driven structural and electrical remodeling contribute to AF via several reported mechanisms, including adiposity, inflammation, fibrosis, oxidative stress, ion channel alterations, and autonomic dysfunction. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration. Weight loss has been shown to reverse these changes and reduce AF risk and recurrence after ablation. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited. In this review, we discuss mechanisms by which obesity mediates AF and treatment outcomes, aiming to provide insight into obesity-drug interactions and guide personalized treatment for this patient subgroup.
Original language | English |
---|---|
Article number | e032277 |
Number of pages | 15 |
Journal | Journal of the American Heart Association |
Volume | 13 |
Issue number | 1 |
Early online date | 29 Dec 2023 |
DOIs | |
Publication status | Published - 2 Jan 2024 |
Bibliographical note
The authors are supported by the British Heart Foundation (PG/17/55/33087, RG/17/15/33106, FS/19/12/342040; FS/PhD/22/29309); British Heart Foundation Accelerator Award to the Institute of Cardiovascular Sciences, University of Birmingham; Wellcome Trust (109604/Z/15/Z; 221650/Z/20/Z); MRC AIM DTP (MR/W007002/1).Keywords
- Humans
- Atrial Fibrillation/epidemiology
- Obesity/complications
- Treatment Outcome
- Adiposity
- Heart Failure
Fingerprint
Dive into the research topics of 'Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options'. Together they form a unique fingerprint.-
Development of novel computational approaches for human cardiac mapping data - Improving understanding and treatment of atrialfibrillation
O'Shea, C. (Principal Investigator)
1/05/21 → 30/04/25
Project: Research
-
Investigating regulatory pathways for intracellular sodium in the atria
Pavlovic, D. (Principal Investigator) & Thomas, S. (Co-Investigator)
1/10/19 → 30/04/23
Project: Research
-
Scarred by kidney disease: FGF23 as a key mediator of cardiac fibrosis in patients with chronic kidney disease
Weston, C. (Co-Investigator), Pavlovic, D. (Co-Investigator), McGettrick, H. (Co-Investigator) & Gough, R. (Principal Investigator)
1/08/19 → 28/02/23
Project: Research
-
Cardiotonic steroids in patients with atrial fibrillation and heart failure: Quantification, functional effects and personalisation of digoxin therapy
Arlt, W. (Co-Investigator), Pavlovic, D. (Principal Investigator), Taylor, A. (Co-Investigator), Kotecha, D. (Co-Investigator) & Kirchhof, P. (Co-Investigator)
1/06/18 → 30/05/21
Project: Research